KR20150067902A - A pharmaceutical composition for preventing and treating sepsis comprising desoxo-narchinol-a and 8??-hydroxypinoresinol as active ingredients - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing and treating sepsis and, more specifically, to a pharmaceutical composition for preventing and treating sepsis or a food composition for preventing or treating sepsis, which contains desoxo-narchinol (DN) A or 8alpha-hydroxypinoresinol (HP) as active ingredients. The composition of the present invention effectively controls inflammation caused by LPS, thereby being effectively used in prevention and treatment of sepsis.

Description

FIELD OF THE INVENTION The present invention relates to a pharmaceutical composition for preventing and treating septicemia comprising as an active ingredient an effective amount of 8-hydroxypinoresinol and 8-hydroxypinoresinol. }

The present invention relates to a pharmaceutical composition for preventing and treating septicemia, and more particularly, to a pharmaceutical composition for preventing and treating septicemia containing dexo-nazzinol A and 8a-hydroxypinoresinol as an active ingredient, And to a food composition for prevention and improvement.

Sepsis is known to be a major cause of morbidity and mortality worldwide, and there are no accurate statistics in Korea, but it is very high. Sepsis is caused by the fact that lipopolysaccharide (LPS), a component of the cell wall, acts as a toxin when the pathogenic Gram-negative bacteria are infected to the living body, resulting in excessive activation of the immune system of the living body. In severe cases, it is accompanied by a shock. Sepsis is a very serious disease with a mortality rate of more than 30%, which is the leading cause of death in hospitalized nurses in hospital intensive care units. Despite the advances in medical technology, sepsis is still common worldwide, In many cases, sepsis occurs when a person with a weak immune system such as a newborn or an elderly person is infected. Antibiotics are usually treated with sepsis. However, antibiotics alone can not provide effective treatment if a large number of microorganisms are proliferated due to delayed appropriate treatment or if the infection is caused by a strain resistant to antibiotics. With the increasing number of pathogens resistant to various antibiotics, its treatment has become a very important issue, but no suitable therapeutic agent has been developed yet.

Interleukin-6, interleukin-1, interleukin-1, interleukin-1, interleukin-1, interleukin-1, interleukin-1 and interleukin- There have been a number of attempts to suppress such mediators, but they have not improved the survival rate of patients. During inflammatory processes, proinflammatory cells (mainly activated macrophages) are activated by cytokines and interleukin (IL) -1β, IL-6, tumor necrosis factor alpha (TNF-α), prostaglandin E2 It is the most cellular and molecular pathophysiological cause of sepsis by producing promoters of other inflammatory responses involving nitric oxide (NO) (Szekanecz Z, Koch AE 2007. Curr Opin Rheumatol 19 : 289-295; Kang YJ, Wingerd BA, Arakawa T et al. 2006. J Immunol 177 : 8111-8122; Noguchi S, Nakatsuka M, Konishi H et al. 2003. Int Immunopharmacol 3 : 1335-1344). Of the various inflammatory mediators, the two most important are NO and PGE2, which are products of the inducible NO synthase (iNOS) and COX-2 (cyclooxygenase-2), respectively (Vane JR, Mitchell JA, Appleton I et al. Proc Natl Acad Sci USA 91 : 2046-2050).

Meanwhile, Nardostachys jatamansi , NJ) has been widely used in several Asian countries to treat palpitations, mental disorders, insomnia, epilepsy, blood disorders, and circulatory diseases. Jatamansic acid, Jatamansone, lignans and neolignans are present in the roots of these plants. Water, which is rooted in ginseng, is used for mental disorders, insomnia, blood disorders and circulatory system disorders. The main therapeutic ingredient of ginseng is nardosinone, which enhances the perfusion and central nervous system (CNS) effects.

The present inventors have previously reported that the masking fragrance has a protective effect on acute pancreatitis and sepsis. However, NJ-isolated compounds exhibiting anti-inflammatory effects on lipopolysaccharide (LPS) have not been studied. Therefore, the present inventors tried to find a compound isolated from NJ showing anti-inflammatory effect. It was found that DN (desoxo-narchinol A) and HP (8α-hydroxypinoresinol) isolated from NJ were expressed in the peritoneal macrophages of LPS- As a result of investigating the inflammatory effect, it was found that DN and HP strongly inhibited the LPS-induced response and HP significantly inhibited the activation of p38 MAPKs. Thus, it was found that the above substances of the present invention can be used as a therapeutic agent for sepsis. .

It is an object of the present invention to provide a substance usable as a pharmaceutical composition for the prevention and treatment of sepsis.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating septicemia comprising desoxo-narchinol (DN) A as an active ingredient,

≪ Formula 1 >

The present invention also provides a pharmaceutical composition for preventing and treating septicemia comprising 8p-hydroxypinoresinol (HP) as an active ingredient.

(2)

The present invention also provides a method for preventing septicemia comprising administering desoxo-narchinol (DN) A of formula 1 and 8-hydroxypinoresinol (HP) of formula 2 as an active ingredient And a pharmaceutical composition for therapeutic use.

And, it is preferable that the DN or HP is separated from the reducing direction, and the active ingredient may further comprise a pharmaceutically acceptable carrier.

The present invention also provides a food composition for preventing and improving septicemia comprising DN or HP as an active ingredient.

Hereinafter, the present invention will be described in detail.

Achieving the Object of the Invention The present inventors have studied the production of inflammatory mediators such as iNOS, NO, COX-2, and PGE2. In addition, the present inventors have studied the production of inflammatory cytokines including TNF-a, IL-l [beta], and IL-6. In addition, to study the mechanism of regulation of DN and HP, the present inventors have studied the activation of mitogen-activated protein kinases (MAPKs) and NF-κB (nuclear factor kappa B).

Gamma-ray has been reported to exhibit anti-inflammatory effects on lipopolysaccharides. However, it has not been known which components from the sorghum produce anti-inflammatory effects.

The present invention provides the effects of DN (Desoxo-Narchinol-A) and HP (8a-hydroxypinoresinol) isolated from hypersensitive to lipid polysaccharide-induced inflammation in rat peritoneal macrophages. The antiinflammatory effect is measured by measuring the induction of nitric oxide synthase and its derivatives such as nitric oxide, cyclooxygenase-2, prostaglandin E2, interleukin-lb, interleukin-6, and tumor necrosis factor alpha . In addition, the present inventors provide regulatory mechanisms based on DN and HP effects. The present inventors have found that both DN and HP inhibit the production of inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2, and prostaglandin E2. DN inhibited interleukin-l [beta], interleukin-6, and tumor necrosis factor alpha, whereas HP inhibited only interleukin-6 and tumor necrosis factor alpha but not interleukin-l [beta]. In addition, treatment with DN or HP inhibits the activation of p38 MAP kinase. Together, the results indicate that DN and HP, isolated from ginsenoside, can be components with effective anti-inflammatory activity individually in mouse macrophages.

Our previous work investigated the anti-inflammatory effects of NJ. However, it is not known which components of NJ produce an anti-inflammatory effect on LPS. Therefore, we separated the two components, DN and HP from NJ. As suggested by the reduced inflammatory mediator production in macrophages in the present invention, DN and HP strongly inhibited the LPS-induced response. In addition, DN and HP significantly inhibited the activation of p38 MAPKs.

Inducible NO synthase may increase cellular NO levels in the micromolar range, which may be important for physiological immune effects that can play an important role in a variety of inflammatory diseases. The elevation of COX-2 activity is responsible for the synthesis of prostanoids that are important for inflammatory responses, including PGE2. In the present invention, DN and HP inhibited iNOS albumen NO production and COX-2-mediated PGE2 synthesis, suggesting that DN and HP could weaken the inflammatory process.

The ligand of toll-like receptor 4, LPS, is capable of inducing a large number of inflammatory-promoting cytokines such as IL-1β, IL-6, and TNF-α and is a potent stimulator of inflammation in macrophages. It is now generally believed that most pathological processes based on inflammatory syndromes are caused by the rapid overproduction of cytokines such as IL-1β, IL-6, and TNF-α. In addition, for sepsis, levels of IL-6 and TNF are elevated in the inflammatory space. Pretreatment of DN and HP reduces LPS-induced upregulation at IL-6 and TNF-alpha protein levels in a dose-dependent manner. DN also inhibited IL-1 [beta] production. These data indicate that inhibition of inflammatory cytokines by DN and HP can contribute to their anti-inflammatory activity.

Inflammation induced by LPS is associated with NO and cytokine upregulation, which ultimately leads to the activation of MAPKs and NF-KB. Generally, the induced MAPKs are p38, ERK1 / 2 and JNK, and MAPKs are frequently activated by self-phosphorylation. However, the activation of NF-κB is mediated primarily by phosphorylation and subsequent degradation of Iκ-Bα. Of the MAPKs, p38 plays an important role in inflammatory cell activation after injury. In the absence of p38, cell priming is not achieved and elevated levels of cytokines seen in p38 [alpha] -co-KO mice do not produce cytokine-level cellular activation or chronic elevation. Therefore, cell activation by p38 is important for maintaining an acute or chronic inflammatory state after an unknown attack, and inhibition or elimination of p38a can increase the outcome. Our results suggest that DN and HP inhibit the activation of p38 but not the activation of ERK1 / 2, JNK, or NF-κB. However, the inhibitory mechanism of DN and HP is different from that of NJ whole extract. NJ extract extract inhibited the activation of all MAPKs, but DN and HP isolated from NJ only suppressed p38 activation, which means that other components from NJ could inhibit ERK1 / 2 and JNK activation. Through further study, there is a need to study the potential of other discrete components from NJ.

Taken together, the inventors have demonstrated the anti-septic effects of DN and HP; DN and HP inhibited inflammatory mediators such as iNOS, NO, COX-2, PGE2, and inflammatory cytokines. Our data suggest that DN and HP isolated from the hypersensitive lesion may provide a potential therapeutic strategy for the prevention of LPS-induced sepsis conditions by inactivation of the p38 pathway.

In addition, the pharmaceutical composition of the present invention may further comprise other herbal medicines or extracts thereof which are pharmaceutically acceptable for enhancing the pharmacological effect. In this case, the active ingredient may be isolated and incorporated into the pharmaceutical composition. The term "pharmaceutically acceptable" as used herein means physiologically acceptable and does not normally cause an allergic reaction or a similar reaction when administered to humans.

The herbal medicine which may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelicae tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhei Rhizoma, Glycyrrhizae Radix, Cnidii Rhizoma, Aurantii nobilis Pericarpium, Alismatis Rhizoma, Coptidis Rhizoma, ), Golden (Scutellariae Radix), Hoelen, Paeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Uncaria Ramuluset Uncus, , Ponciri Fructus, Ginseng, Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Atractylodis Rhizoma alba, Chrysanthemi Flos, Ledebouriellae Radix, Ginger (Zingiberis Rhizoma crudus), mangrove (Natri i sulfas, Zizyphi Fructus, Salviae Radix, Mautan Radicis Cortex, Rehmanniae Radix, Menthae Herba, Dioscoreae Rhizoma, Polyporus, Polygonimultiflori Radix ), Allii tuberosi Semen, Cassiae Semen, Lycii Fructus, Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisia cecillatus Herba, Anemarrhenae Rhizoma, Carthami Flos, Astragali Radix, Lycopodium, Ginkgonis Folium, Polygonati Rhizoma, Nelumbinis Semen, Fossilia ossis Mastodi, , Lycia radicis Cortex, Achyranthis Radix, Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Hordei Fructus germinatus, Cuscutae Semen, Morindae Radix ), Sea horse (Pini koraiensis Radix) Or may be used in combination.

In addition, the pharmaceutical composition according to the present invention may further contain one or more pharmaceutically acceptable carriers, excipients or diluents.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.

Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.

In addition, the carrier for parenteral administration may contain water, a suitable oil, a saline solution, an aqueous glucose and a glycol, and may further contain a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).

The pharmaceutical composition for preventing or treating septicemia of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration Lt; / RTI > Preferably, the pharmaceutical composition of the present invention can be transdermally administered. The term " transdermal administration " refers to administering the pharmaceutical composition of the present invention to cells or skin to allow the active ingredient contained in the pharmaceutical composition for prevention or treatment of inflammation to be delivered into the skin. For example, the pharmaceutical composition of the present invention can be administered in a scanning type formulation, pricking the skin lightly with a 30 gauge needle, or directly applying it to the skin.

The pharmaceutical composition of the present invention may be formulated into oral or parenteral dosage forms according to the route of administration as described above.

In the case of a preparation for oral administration, the composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a liquid, a gel, a syrup, a slurry, . For example, an oral preparation can be obtained by combining the active ingredient with a solid excipient, then milling it, adding suitable auxiliaries, and then processing the mixture into a granular mixture. Examples of suitable excipients include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition of the present invention may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In the case of a preparation for parenteral administration, it can be formulated by a method known in the art in the form of injection, cream, lotion, external ointment, oil, moisturizer, gel, aerosol and nasal aspirate. These formulations are described in Remington's Pharmaceutical Science, 15th edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a commonly known formulary for all pharmaceutical chemistries.

The total effective dose of DN and HP, the active ingredients of the compositions of the present invention, may be administered to a patient in a single dose and may be administered to a fractionated treatment protocol administered prolonged at multiple doses ≪ / RTI > In the pharmaceutical composition of the present invention, the content of the active ingredient may be varied depending on the degree of the disease. Preferably, the preferred total dose of DN and HP of the present invention may be from about 1 μg to 5 mg, most preferably from 5 μg to 1 mg per kg of patient body weight per day. However, the above-mentioned DN and HP doses can be effectively administered to patients in consideration of various factors such as age, weight, health condition, sex, severity of disease, diet and excretion rate of the patient as well as route and frequency of administration of the pharmaceutical composition In view of this point, those of ordinary skill in the art will be able to determine the appropriate effective dose of DN and HP according to the particular use as a prophylactic or therapeutic agent for septicemia. The pharmaceutical composition according to the present invention is not particularly limited to its formulation, administration route and administration method as long as the effect of the present invention is exhibited.

The present invention also provides a food composition for preventing and improving septicemia comprising the DN of Formula 1 as an active ingredient.

In the food composition for preventing and improving septicemia according to the present invention, it is preferable that, in addition to DN, the HP of formula (2) is further contained as an active ingredient.

The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, as a health food, the DN and HP of the present invention can be prepared in the form of tea, juice, and drink, and then consumed for drinking, granulated, encapsulated and powdered. In addition, DN and HP of the present invention can be prepared in the form of a composition by mixing together with a known substance or active ingredient known to be effective for preventing and improving septicemia.

Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (e.g., canned fruits, bottled, jam, maalmalade, etc.), fish, meat and processed foods such as ham, Etc.), breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, Retort foods, frozen foods, various seasonings (e.g., soybean paste, soy sauce, sauces, etc.) by adding the DN and HP of the present invention.

In addition, in order to use the DN and HP of the present invention in the form of a food additive, they may be used in the form of powders or concentrates.

The present invention provides a composition for preventing and treating sepsis comprising DN and HP of the present invention as an effective ingredient. The DN and HP-containing compositions of the present invention effectively inhibit the inflammation caused by LPS and thus can be effectively used for the prevention and treatment of sepsis.

Figure 1 shows the effect of DN and HP on peritoneal macrophage cell viability. Cells were cultured with DN or HP at the indicated doses. After 24 hours, the cell viability was measured by the MTT assay described in the examples. Data are the mean of three independent experiments (# p <0.001 vs. DMSO).
Figure 2 shows the effect of DN and HP on iNOS and NO production. Cells were cultured with DN or HP at the indicated concentrations for 1 hour and then incubated with 500 ng / ml LPS for 24 hours. (A, C) LPS-induced iNOS expression was measured by Western blot analysis. (B, D) Griess reaction. Data are mean of 3 independent experiments (* p < 0.05 vs. DMSO; + p < 0.05 vs. LPS).
Figure 3 shows the effect of DN and HP on the production of COX-2 and PGE2. Cells were pre-treated with DN or HP at the indicated concentrations for 1 hour and then incubated with 500 ng / ml LPS for 24 hours. LPS-induced COX-2 expression was measured by (A, C) Western blot analysis. PGE2 release was measured by (B, D) ELISA. Data are mean of 3 independent experiments (* p < 0.05 vs. DMSO; + p < 0.05 vs. LPS).
Figure 4 shows the effect of DN and HP on the production of IL-1 [beta], IL-6 and TNF- [alpha], pretreating cells with DN or HP at the indicated concentrations for 1 hour and then 500 ng / LPS. Levels of cytokines in supernatants were determined by ELISA. The detailed description is given in the examples. Data are mean of 3 independent experiments (* p < 0.05 vs. DMSO; + p < 0.05 vs. LPS).
Figure 5 shows the effect of DN and HP on the activation of MAPKs. Cells were pre-treated with DN or HP for 1 hour and then incubated with 500 ng / ml LPS for the indicated times. The detailed description is given in the examples. A representative Western blot of three separate experiments was described.
Figure 6 shows the effect of DN and HP on Iκ-Bα degradation. Cells were pre-treated with DN or HP for 1 hour and then incubated with 500 ng / ml LPS for the indicated times. The detailed description is given in the examples. Data is the average of three independent experiments.
7 is a chemical formula showing the structure of (A) DN and (B) HP of the present invention.

Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the drawings. However, it should be understood that the following embodiments are provided so that those skilled in the art may understand the present invention without departing from the scope and spirit of the present invention. It is not.

Reference Example 1: Statistical analysis

All data were expressed as mean ± standard deviation of independent experiments. Two-way ANOVA was used to analyze the statistical significance of the results between two groups or between three or more groups. All statistical analyzes were performed using SPSS, version 10.0 statistical analysis software.

Reference Example 2: Compound and reagent

RPMI-1640 (Roswell Park Memorial Institute culture medium), fetal bovine serum (FBS), penicillin and streptomycin were purchased from Gibco BRL (Grand Island, NY, USA). An ELISA kit was purchased from R & D Systems (Minneapolis, Minn., USA) for the detection of mouse IL-1β, IL-6, and TNF-α. LPS from E. coli 055: B5 was purchased from Sigma-Aldrich Chemical (St. Louis, MO, USA). Antibodies to whole and phosphorus-specific MAPKs (p38; extracellular signal-regulated kinase 1/2 [ERK 1/2]; c-Jun NH 2 -terminal protein kinase [JNK] Beverly, MA, USA). Iκ-Bα (Inhibitory kappa-Bα) monoclonal antibody and peroxidase-conjugated secondary antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Pre-stained SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) markers were purchased from Bio-Rad (Hercules, CA, USA). The TRIzol reagent and PCR (polymerase chain reaction) kit were purchased from Invitrogen Corporation (Carlsbad, CA, USA).

<Reference Example 3> Tool

Nuclear magnetic resonance spectra were recorded using a JEOL Eclipse-500 MHz spectrometer (500 MHz for 1 h) and chemical shifts were measured based on tetramethylsilane. Column chromatography was performed on silica gel 60-precoated plates (70-30 mesh, Merck) and YMC gel (YMC Co. Ltd., Japan) -coated plates. Light Chromatography (TLC), silica gel F254 (0.2 mm, Merck) and RP-18 F254s plates (0.2 mm, Merck) were used. Spots were detected after heating after UV light or spray with 10% sulfuric acid solution.

&Lt; Example 1 > Extraction and Separation

NJ was extracted from hydrothermal fluid. The NJ extract (15 g) was dissolved in distilled water, and after fractionation with ethyl acetate (EtOAc), it was fractionated with n-butanol. Six fractions (Fr. 1-6) were obtained with a silica gel column (6.5 x 60 cm) using n-hexane / EtOAc (4: 1 to 1: 2) as eluant and the resulting EtOAc- .

An additional four fractions (Fr. 2-1 to 2-4) were obtained on a reversed phase (YMC Gel ODS-A, S-75 urn) column (3 X 25 cm) using MeOH / H ₂ O , And as a result, fraction 2 (468.7 mg) was isolated. Fraction 2-2 (137.7 mg) was purified using medium pressure liquid chromatography (MPLC) (column: SI-40 A, 11 mm x 300 mm) eluting with dichloromethane / MeOH (30: To give DN (43.7 mg) (Fig. 7A). Spectral data were the same as reported in the literature (Itokawa et al., 1993). Five fractions (Fr. 5-1 to 5-5) were obtained, and as a result, fraction 5 (201.9 mg) was purified. Fractions 5-2 (41.3 mg) and 5-3 (24.9 mg) were obtained using MPLC using MeOH / H ₂ O (1: 2) as an eluent to give HP (27.4 mg) 7, B). Spectral data were the same as reported in the literature.

Example 2: Peritoneal macrophage culture

All experiments were carried out according to the protocol approved by the Wonderland Animal Care Committee. Six to eight weeks old female C57BL / 6 mice weighing 15-20 g were purchased from Orient Bio (Sungnam, KyungKiDo, South Korea). All animals were housed and resident in a standard shoe boxed cage in a climate-controlled room with an ambient temperature of 23 ± 2 ° C and a 12-hour darkness cycle for 7 days. Thioglycollate (TG) -induced peritoneal macrophages were harvested 4 days after intraperitoneal injection of 3 ml TG. Peritoneal perfusion was performed using 8 ml of RPMI medium supplemented with 10% heat-inactivated FBS. After incubation for 3 hours, unattached peritoneal cells were removed and replaced with cells to which the medium was attached.

&Lt; Example 3 > MTT analysis

Cell activation has been previously reported (Bae GS, Seo SW, Kim MS, et al 2011. J Nat Med 65 : 6372).

Example 4 Measurement of NO Concentration

Macrophages (2 × 10 ⁵ cells / well) were pretreated with DN and HP for 1 hour and then stimulated with LPS (500 ng / mL) for 24 hours. To determine the NO concentration, 100 μl fractions were isolated from the conditioned media and incubated for 10 min at room temperature with the same amount of Griess reagent (1% sulfanilamide / 0.1% N- (1-naphthyl) -ethylenediamine dihydrochloride / 2.5% phosphoric acid) Lt; / RTI &gt; The absorbance was then measured at 540 nm.

&Lt; Example 5 > PGE2 analysis

The level of PGE2 was measured using an immunoassay kit according to the manufacturer's protocol (Stressgen Biotechnologies, MI, USA).

&Lt; Example 6 > Western blot analysis

Macrophages (5 × 10 ⁶ cells / well) were pretreated with DN and HP for 1 hour, then stimulated with LPS (500 ng / mL). Whole cell lysates were prepared by boiling the macrophages in the same buffer (62.5 mM Tris-HCl [pH 6.8], 2% SDS (sodium dodecyl sulfate), 20% glycerol and 10% 2-mercaptoethanol). Proteins in cell lysates were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. COX-2, phosphorylated p38, phosphorylated ERK1 / 2, phosphorylated JNK, and Iκ-Bα in 5% skim milk in PBS containing 0.05% Tween-20 at room temperature for 2 hours Lt; / RTI &gt; antibody. After 3 washes in PBST, each blot was incubated with the corresponding secondary antibody for 1 hour and analyzed using an enhanced chemiluminescence detection system (Amersham, Piscataway, NJ, USA) according to the manufacturer's recommended protocol The antibody-specific protein was visualized.

<Example 6> ELISA analysis

Macrophages (1 × 10 ⁶ cells / well) were pre-treated with DN and HP for 1 hour, and then stimulated with LPS (500 ng / mL) for 24 hours. The culture supernatant was collected and stored at -70 ° C until use. ELISAs for IL-1 [beta], IL-6, and TNF- [alpha] were performed in duplicate; 96-well plates were coated overnight at 4 ° C with 100-μl solutions of anti-mouse IL-1β, IL-6, and TNF-α monoclonal antibodies in PBS (pH 7.4). The plate was washed with PBS containing 0.05% Tween-20 and the plate was blocked with PBS containing 10% FBS for 2 hours. After further washing, standards and samples were added and incubated at room temperature (RT) for 2 hours. The wells were washed and incubated for 1 hour at RT with addition of biotinylated anti-mouse IL-1β, IL-6, or TNF-α. The wells were washed, and avidin-peroxidase was added and incubated at RT for 30 min at RT followed by repeated washing and addition of TMB substrate. The color change was measured at 450 nm in an automated microplate ELISA recorder. Standard samples were run on each measurement plate using serial dilutions of recombinant IL-1 [beta], IL-6, and TNF- [alpha].

<Result 1> Effect of DN and HP on cytotoxicity in rat peritoneal macrophages

To investigate the effects of DN and HP on cell activation, we performed MTT assays on rat peritoneal macrophages. Cells were incubated with DN and HP for 24 h at the indicated doses (Figure 1). DN and HP affected cell-activated cytotoxicity at levels greater than 500 nM and 1,000 nM, respectively (* p <0.001) (Fig. 1). Therefore, the present inventors used a concentration range of 50 to 500 nM for DN and 100 to 1000 nM for HP.

<Result 2> LPS -Judo iNOS  And NO  On creation DN  And HP Effect of

We investigated the effects of DN and HP on the expression of iNOS and NO in LPS-stimulated macrophages. Pretreatment of DN or HP inhibited LPS-induced iNOS expression in a dose-dependent manner (Figures 2A and 2C). Consistent with iNOS results, pre-treatment of DN or HP also inhibited LPS-induced NO production in a dose-dependent manner (FIGS. 2B and 2D).

<Result 3> Effects of DN and HP on the production of LPS-induced COX-2 and PGE2

For 1 hour, macrophages were pretreated with the indicated concentrations of DN or HP and then stimulated with LPS at 500 ng / mL for 24 hours. Pretreatment of DN or HP reduced LPS induced upregulation at the COX-2 level (Figures 3A and 3C). Since PGE2 is the result of COX-2 activation, we measured PGE2 production in peritoneal macrophages. Similar to COX-2 results, pretreatment of DN or HP inhibited LPS-induced PGE2 production in a dose-dependent manner (FIGS. 3B and 3D).

<Result 4> Effects of DN and HP on LPS-induced upregulation of L-1β, IL-6, and TNF-α production

To investigate the effects of DN and HP on inflammatory responses induced by LPS, we analyzed the production of the inflammatory response-promoting cytokines IL-1β, IL-6, and TNF-α. Pretreatment of DN inhibited LPS-induced IL-1β, IL-6, and TNF-α production in a dose-dependent manner (FIG. 4A). Pretreatment of HP also inhibited LPS-induced upregulation of IL-6 and TNF-a in a dose-dependent manner, but did not inhibit the production of IL-1 [beta] (FIG. 4B).

<Result 5> Effect of DN and HP on activation of MAPKs

To investigate the inhibitory mechanism of DN and HP on inflammatory mediators, we investigated the MAPK pathway. Cells were treated with DN or HP for 1 hour, and then stimulated with LPS for the indicated times (Figure 5). However, DN and HP pretreatment inhibited phosphorylation of p38, but did not inhibit phosphorylation of ERK and JNK (FIGS. 5A and 5B).

<Result 6> Effect of DN and HP on the activation of NF-κB

To measure the pretreatment effects of DN and HP on the activation of NF-κB, cells were treated with DN or HP for 1 hour, and then stimulated with LPS for the indicated times (FIG. 6). We measured NF-κB activity by measuring degradation of Iκ-Bα. As shown in Fig. 6, the LPS treatment resulted in NF-kB activation through Iκ-Bα degradation. Pretreatment of DN or HP has no effect on the level of NF-κB, as shown by the lack of inhibition of Iκ-Bα degradation (FIGS. 6A and 6B).

<Other Manufacturing example > DN  And HP Production of functional food containing active ingredient

The inventors of the present invention have confirmed that DN and HP components are excellent in anti-inflammatory activity through the above examples, and prepared a functional food containing the active ingredient as follows.

&Lt; Preparation of beverage &

0.75 to 1.28 mg of DN and HP (1: 1 weight ratio), 50 mg of nitrosammonium chloride, 3 mg of sodium riboflavin hydrochloride, 2 mg of pyridoxine hydrochloride, 30 mg of inositol, 200 ml

A beverage was prepared using the above-mentioned composition and content by a conventional method.

&Lt; Preparation of chewing gum &

(1: 1 weight ratio) 0.24 ~ 0.64%, Fruit flavor 1%, Water 2%, Sugar 76.36 ~ 76.76%, Gum base 20%

Chewing gum was prepared using the above-mentioned composition and content by a conventional method.

&Lt; Preparation of candy &

50 to 60% of sugar, 39.26 to 49.66% of starch syrup, 0.24 to 0.64% of DN and HP (1: 1 weight ratio), 0.1%

The composition and the content of the candy were prepared using a conventional method.

&Lt; Preparation of ice cream &

(1: 1 weight ratio), 10% of milk fat, 10.8% of nonfat solid, 12.0% of sugar, 3.0% of starch syrup, 0.5% of span and span, 0.15% of perfume (Strawberry), 63.31 to 62.91% ) 0.24 to 0.64%

Ice cream was prepared using the above-mentioned composition and content by a conventional method.

< Of chocolate  Manufacturing>

Sugar 34.36 ~ 34.76%, cocoa butter 34%, cocoa mass 15%, cocoa powder  15%, lecithin 0.5%, vanilla flavor 0.5%, DN and HP (1: 1 weight ratio) 0.24 to 0.64%

The composition and the content thereof were used to prepare chocolate by a conventional method.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, This is possible.

Claims (6)

A pharmaceutical composition for preventing and treating septicemia comprising desoxo-narchinol (DN) A as an active ingredient,

&Lt; Formula 1 > A pharmaceutical composition for preventing and treating septicemia comprising 8? -Hydroxypinoresinol (HP) as an active ingredient.

(2) A pharmaceutical composition for preventing and treating septicemia, which comprises desoxo-narchinol (DN) A in the formula (1) and hydroxypinoresinol (HP) in the formula Gt;

&Lt; Formula 1 >

(2) 4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the DN or HP is separated from the sorghum. The pharmaceutical composition for preventing and treating sepsis according to any one of claims 1 to 3, wherein the active ingredient further comprises a pharmaceutically acceptable carrier. A food composition for preventing and improving septicemia comprising DN or HP according to any one of claims 1 to 3 as an active ingredient.

Images